GlaxoSmithKline Plc (Mexico) Performance
| GSKN Stock | MXN 739.40 0.57 0.08% |
The company retains a Market Volatility (i.e., Beta) of 0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GlaxoSmithKline Plc's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline Plc is expected to be smaller as well. GlaxoSmithKline plc right now retains a risk of 2.1%. Please check out GlaxoSmithKline Plc coefficient of variation, variance, and the relationship between the mean deviation and standard deviation , to decide if GlaxoSmithKline Plc will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GlaxoSmithKline plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, GlaxoSmithKline Plc is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 3.8 B |
GlaxoSmithKline |
GlaxoSmithKline Plc Relative Risk vs. Return Landscape
If you would invest 74,306 in GlaxoSmithKline plc on September 2, 2024 and sell it today you would lose (366.00) from holding GlaxoSmithKline plc or give up 0.49% of portfolio value over 90 days. GlaxoSmithKline plc is generating 0.0137% of daily returns and assumes 2.0983% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than GlaxoSmithKline, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
GlaxoSmithKline Plc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlaxoSmithKline Plc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GlaxoSmithKline plc, and traders can use it to determine the average amount a GlaxoSmithKline Plc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0066
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GSKN |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GlaxoSmithKline Plc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline Plc by adding GlaxoSmithKline Plc to a well-diversified portfolio.
GlaxoSmithKline Plc Fundamentals Growth
GlaxoSmithKline Stock prices reflect investors' perceptions of the future prospects and financial health of GlaxoSmithKline Plc, and GlaxoSmithKline Plc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlaxoSmithKline Stock performance.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X | |||
| Price To Sales | 37.65 X | |||
| Revenue | 29.32 B | |||
| EBITDA | 8.8 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 49.71 X | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (3.7 B) | |||
| Current Asset | 15.83 B | |||
| Current Liabilities | 13.92 B | |||
About GlaxoSmithKline Plc Performance
Evaluating GlaxoSmithKline Plc's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GlaxoSmithKline Plc has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GlaxoSmithKline Plc has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GLAXOSMITHKLINE is traded on Mexico Stock Exchange in Mexico.Things to note about GlaxoSmithKline plc performance evaluation
Checking the ongoing alerts about GlaxoSmithKline Plc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlaxoSmithKline plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating GlaxoSmithKline Plc's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate GlaxoSmithKline Plc's stock performance include:- Analyzing GlaxoSmithKline Plc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlaxoSmithKline Plc's stock is overvalued or undervalued compared to its peers.
- Examining GlaxoSmithKline Plc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlaxoSmithKline Plc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlaxoSmithKline Plc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlaxoSmithKline Plc's stock. These opinions can provide insight into GlaxoSmithKline Plc's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GlaxoSmithKline Stock Analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.